PMID- 31464618
OWN - NLM
STAT- MEDLINE
DCOM- 20200106
LR  - 20200225
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 19
IP  - 1
DP  - 2019 Aug 29
TI  - Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell 
      line (BPH-1) through p38 MAPK-FOXO3a pathway.
PG  - 233
LID - 10.1186/s12906-019-2648-8 [doi]
LID - 233
AB  - BACKGROUND: Resveratrol is reported to inhibit the growth of prostate, which is 
      characteristic of benign prostatic hyperplasia (BPH) condition. However, the 
      mechanism remains unclear. This study aimed to identify the effects and probable 
      mechanism of resveratrol on BPH. METHODS: We used the BPH epithelial cell line 
      BPH-1 to investigate the effect of resveratrol. Cells were treated with various 
      concentrations of resveratrol, and its effects on cells viability, apoptosis, ROS 
      accumulation, and cell cycle were assessed. Western blot was used to examine 
      activation of p38 MAPK and protein levels of FOXO3a, Bcl2, Bcl-XL, and caspase3. 
      Cells were also co-treated with the p38 MAPK inhibitor SB203580 or ROS scavenger 
      N-Acetyl-L-cysteine (NAC) to further investigate the mechanism. RESULTS: 
      Resveratrol treatment inhibited the growth of BPH-1 and increased apoptosis of 
      cells. In addition, levels of phosphorylated p38 MAPK level was elevated and 
      FOXO3a repression was observed. Concomitantly, ROS was accumulated. All of these 
      resveratrol-mediated effects were suppressed by additional treatment with 
      SB203580 or NAC. Resveratrol was also found to induce cell cycle arrest at S 
      phase. CONCLUSIONS: Resveratrol can activate p38 MAPK and repress FOXO3a, thereby 
      causing repression of SOD2, catalase, and increase of ROS accumulation, leading 
      to apoptosis in BPH-1 cells.
FAU - Li, Chao
AU  - Li C
AD  - Department of Urology, Zhongnan Hospital of Wuhan University, No. 169 DongHu 
      Road, WuChang District, Wuhan, 430000, Hubei, People's Republic of China.
AD  - Department of Obstetrics and Gynaecology, Wuhan Fourth Hospital; Puai Hospital, 
      Tongji Medical College, Huazhong University of Science and Technology, No.473 
      HanZheng Street, QiaoKou District, Wuhan, 430000, Hubei, People's Republic of 
      China.
FAU - Hu, Wan-Li
AU  - Hu WL
AD  - Department of Urology, Zhongnan Hospital of Wuhan University, No. 169 DongHu 
      Road, WuChang District, Wuhan, 430000, Hubei, People's Republic of China. 
      huwanli_urology@163.com.
FAU - Lu, Meng-Xin
AU  - Lu MX
AD  - Department of Urology, Zhongnan Hospital of Wuhan University, No. 169 DongHu 
      Road, WuChang District, Wuhan, 430000, Hubei, People's Republic of China.
FAU - Xiao, Guan-Fa
AU  - Xiao GF
AD  - Department of Urology, Zhongnan Hospital of Wuhan University, No. 169 DongHu 
      Road, WuChang District, Wuhan, 430000, Hubei, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20190829
PL  - England
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
RN  - 0 (FOXO3 protein, human)
RN  - 0 (Forkhead Box Protein O3)
RN  - 0 (Reactive Oxygen Species)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Forkhead Box Protein O3/*metabolism
MH  - Humans
MH  - Male
MH  - Prostatic Hyperplasia/*metabolism
MH  - Reactive Oxygen Species/metabolism
MH  - Resveratrol/*pharmacology
MH  - Signal Transduction/*drug effects
MH  - p38 Mitogen-Activated Protein Kinases/*metabolism
PMC - PMC6714439
OTO - NOTNLM
OT  - Apoptosis
OT  - Benign prostatic hyperplasia
OT  - FOXO3a
OT  - Reactive oxygen species
OT  - Resveratrol
OT  - p38 MAPK
COIS- The authors declare that they have no competing interests.
EDAT- 2019/08/30 06:00
MHDA- 2020/01/07 06:00
PMCR- 2019/08/29
CRDT- 2019/08/30 06:00
PHST- 2018/12/29 00:00 [received]
PHST- 2019/08/21 00:00 [accepted]
PHST- 2019/08/30 06:00 [entrez]
PHST- 2019/08/30 06:00 [pubmed]
PHST- 2020/01/07 06:00 [medline]
PHST- 2019/08/29 00:00 [pmc-release]
AID - 10.1186/s12906-019-2648-8 [pii]
AID - 2648 [pii]
AID - 10.1186/s12906-019-2648-8 [doi]
PST - epublish
SO  - BMC Complement Altern Med. 2019 Aug 29;19(1):233. doi: 10.1186/s12906-019-2648-8.